VIDEO

No patient should be denied the cancer care they need simply because some options are in short supply or unavailable. Yet, all too often. This is what happens. Next generation cancer treatments are being held back because the active ingredients needed for advanced therapies and new methods of diagnosis are scarce. Many existing manufacturing techniques and facilities relied upon by drugmakers around the world are outdated, inefficient, or have limited production capabilities. This threatens the ability to meet current patient needs and stifles innovation. We need new solutions. That's where Nusano comes in. Nusano is a medical technology company that produces radioisotopes, tiny tracers used by doctors to diagnose and treat cancer and other diseases. Health care has used radioisotopes for decades. But supply hasn't kept up with demand, leaving patients without the benefits of these lifesaving, proven tools. Nusano’s patented technologies and methods are poised to transform medical radioisotope production and help usher in an exciting new era in cancer care. We've developed a process that is smaller, safer, and more efficient than existing technologies to reliably produce the active ingredients at the heart of next generation cancer treatments and diagnostic techniques. Opening in 2025, our state-of-the-art facility in Utah’s Salt Lake Valley will produce medical radioisotopes quickly and affordably, making desperately needed resources available to patients around the world and offering those with life threatening diseases, hope for a healthier tomorrow.

The Nusano production platform enables the simultaneous production of a wide variety of radioisotopes at unprecedented quantities. The process begins with Nusano's patented ion source. Here, heavy ions are created at rates hundreds of times greater than existing commercial systems. From the source, these particles are focused into a linear accelerator. The ions are bunched together in the drift tube section of the accelerator and sped up as they pass through a series of electromagnetic fields. In the case of alpha ions, the particles reach a speed approximately one-sixth the speed of light. Pulses of these ions then travel through a series of magnets as a beam. The magnets direct each pulse to one of 12 targets. Toward the end of the journey, these magnets also spread the beam out, so it is evenly distributed over the entire target surface. Seen from inside the beam, the particles are flowing toward a square target. When they collide with the target material nucleus, a radioisotope is created. The Nusano platform is capable of producing up to 12 different isotopes simultaneously. A giant leap forward, enabling commercial scale production of the active pharmaceutical ingredients needed for next generation cancer diagnostics and therapeutics.

GOV. COX: It is truly an honor to be here with all of you today on this very special, historic day for Nusano. They’re actually shaping the future of healthcare, clean energy, and national security. Things that we all desperately need to solve, and they're doing it right here in West Valley City, Utah. JOHN DAHLSTROM, WASATCH GROUP: Users of this technology in their development of drugs that will help to cure cancer. This is really the start of what we see as a hub for innovation here in Utah. Innovation around the production of radioisotopes. GOV. COX: If some of you are not familiar with Nusano and what they do you will be. I truly believe that over the next few years, it will become a household name. CHRIS LOWE, NUSANO CEO: All this wouldn't have been possible without the vision of our two co-founders, Dr. Glenn Rosenthal, Dr. Howard Lewin. We owe them a debt of gratitude. Thank you.

Nusano is a privately held physics company working to stabilize supply chains and advance American national security. Headquartered in West Valley City, Utah, Nusano is commercializing platform technologies for radioisotope production, stable isotope enrichment and advanced separation techniques. Together, these proprietary systems and methods are poised to supply the fight against cancer, fuel the nuclear renaissance and deliver critical minerals for the modern world. One of the things I like best about working on USADA is the cutting edge technology, we get to work on. It's never a dull moment here. Things rapidly change, and it's really fun to work with all these different people here for a common goal. This company is really unique, and that's one of the things that I love about it. The people that I work with are very smart, they're intelligent, and to be a part of that is extremely rewarding. Our isotopes are a critical part of the solution to global supply challenges in nuclear medicine, and I get to help customers navigate that every day.

VOICEOVER: The 2025 Innovation Impact award goes to Nusano. KRUSE: When you go for cancer treatment, traditionally you go through chemo and radiation. So, today there's a shortage of targeted therapy and access to targeted therapy, and so if we can change that we truly will be a disruptor in the market. MOFFITT: Typically, when you look at radioisotopes they’re produced either in nuclear reactors or with accelerators. And typically when you produce them with accelerators, there’re relatively small quantities, and they’re quite expensive to produce. The unique technology that Nusano brings to bear is our accelerator can produce isotopes of a scale that's 10 to 100 times greater than than any other accelerator out there. So it really puts us in a unique spot. LOWE: Nusano has three foundational technologies. Number one: we have an isotope production facility, which is founded upon our novel ion source. MOFFITT: And it's so revolutionary because it allows us to get very, very high production and very reliable production of many isotopes that are currently unavailable at scale on the market. This opens up options for treatment with a drug like astatine, and really allows more patients to get this novel, very exciting new type of therapy that has the potential to get far better clinical outcomes than chemotherapy or other types of cancer therapy. LOWE: Number two is our stable isotope program. Stable isotopes are basically the starting material for the production of isotopes. Today, over 95% of that material comes from Russia. We produce all of our isotopes with a 100% domestic supply chain. So we remove any geopolitical risk and tariff risk in the interruption of supply for any of of these materials. Our third technology, is our suite of enrichment technologies, specifically plasma enrichment. This allows us to take inanimate objects, convert them into plasma and enrich the specific isotope or element that we're after. This is relevant in the world of life sciences because it allows us to ensure that the product we’re delivering is actually pure and of higher concentration. KRUSE: Most of the technology today to make Isotopes, you can do one or two isotopes at a time. Nusano has the technology to become the Baskin-Robbins of isotopes. We can make multiple concoctions, at multiple times, at massive scale. MOFFITT: It attracts a lot of people to the state of Utah to be near us. And the reason why is you kind of have to think about radioactive material that we're producing like ice cubes. Our material is decaying, the longer it exists. So every half-life, half of it’s gone. And so a lot of these companies want to locate near us. LOWE: We've got about eight to 10 companies that have co-located, or are in the midst of negotiating leases, right within about a half-mile radius of our facility. MOFFITT: Nusano originally started in Southern California. So Glenn, when he first had the idea was a professor at UCLA. After inventing it, we really look at how business-friendly the state of Utah is and the opportunities here. And then found the right partner in Wasatch who was the investor who have the money to build our building and get us started here at Utah. The innovative technology that Nusano has is really so special because of the type of therapy for patients that it opens up. It's going to transform the way that people are able to get cancer therapy. It's also transformative specifically to Utah because it allows Utah to become a hub for a lot of this research and a lot of this type of therapy, as well as being a large economic player within Nusano, providing high-quality jobs and really allowing growth within this space as other companies come and to locate to be near Nusano.

To give you a little bit of background, so I prior to joining NuSano was a professor in the Department of Radiation Oncology, at the University of Washington in Seattle. And there we would produce some of these isotopes that NuSano would be producing. But it was done at a much smaller scale. So NuSano's groundbreaking technology allows us to produce isotopes with our technology that is at a scale of about ten times the rest of the world combined for the type of accelerator we have. You know, it was really exciting when I I joined NuSano to see this opportunity and see what kind of impact it could make on the world. So my advice for somebody just entering the healthcare field would be to make sure you think about it creatively. There's lots of different ways that you can impact healthcare from the science and R and D side of things to treating patients as a nurse or a doctor. I think making sure that you keep your eyes open and find what niche is best for you is gonna be really important. I think a lot of that comes from exploring, from volunteering, getting involved in many different causes that touch the healthcare system.